LENZ THERAPEUTICS INC (LENZ)
Health Care · Ophthalmic pharmaceuticals / presbyopia treatments · NASDAQ
LENZ commercializes VIZZ, the first FDA-approved aceclidine-based eye drop for presbyopia, targeting a $3B+ U.S. market.
What LENZ THERAPEUTICS INC does
LENZ is a commercial pharmaceutical company focused on developing and commercializing innovative therapies to improve vision. The company launched VIZZ (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for presbyopia, in the U.S. in August 2025. VIZZ is a once-daily eye drop designed to restore clear near vision for up to 10 hours by achieving a sub-2mm pupil through a pupil-selective miotic mechanism that minimizes ciliary muscle stimulation. LENZ is also establishing international licensing partnerships to expand access to VIZZ globally.
Themes: ["presbyopia / age-related vision"]
Fundamentals
- Price$5.79 as of 2026-07-09 close
- Market cap$182M as of 2026-07-10
- 1-year return-80.5% as of 2026-07-09 close
- Net margin-519.3% as of 2026-07-10
- Gross margin+97.8% as of 2026-07-10
- ROE-37.6% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Beta2.06 as of 2026-07-10
Key risks (from latest filing)
["Unprofitable with accumulated deficit of $268.6 million and significant ongoing commercialization expenses; dependence on limited cash runway to reach positive operating cash flow."]
Competitors & peers
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.